Protocol TG-402 · Phase III · Oncology
Executive Command Center
Weighted site risk index recomputed from live enrollment, attrition and audit-compliance feeds. Rs = 0.4·(1 − Eactual/Etarget) + 0.3·Pdrop + 0.3·(1 − Caudit).
Feeds live · CTMS, IRT, eTMF
Total active sites
24
0 flagged critical · 3 pending activation
Patient enrollment
599/720
83.2% of Phase III target · +34 last 30d
Compliance score
83.9%
21 CFR Part 11 + ICH GCP E6(R3) weighted
Operational savings (L_saved)
$4,182,400
accruing in real time
Risk-based monitoring vs. 100% SDV baseline
Site portfolio
Risk-ranked site performance
| Site name | Location | Enrollment % | Attrition (P_drop) | Compliance (C_audit) | Risk index (R_s) |
|---|---|---|---|---|---|
Rio Branco Instituto S-119 · Dr. M. Duarte | São Paulo, BR | 49% | 24.0% | 63.0% | 0.389Stable |
Weser Studienzentrum S-138 · Dr. J. Vogt | Bremen, DE | 40% | 17.0% | 78.0% | 0.357Stable |
Cedar Valley Research S-104 · Dr. L. Okafor | Denver, CO | 51% | 19.0% | 71.0% | 0.339Stable |
Mersey Clinical Unit S-123 · Dr. P. Nolan | Liverpool, UK | 84% | 13.0% | 86.0% | 0.146Stable |
Alberta Trials Institute S-131 · Dr. S. Whitfield | Calgary, CA | 80% | 9.0% | 92.0% | 0.131Stable |
St. Aubin Hospital S-107 · Dr. C. Marchand | Lyon, FR | 84% | 11.0% | 89.0% | 0.130Stable |
Kanto University Clinic S-112 · Dr. H. Sato | Yokohama, JP | 92% | 5.0% | 95.0% | 0.061Stable |
Northfield Medical Center S-101 · Dr. A. Rehman | Boston, MA | 93% | 6.0% | 97.0% | 0.054Stable |